1268519-99-8

Basic information

• Product Name: (3S,4R)-1-benzyl-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid
• Synonyms: (3S,4R)-1-benzyl-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid
• CAS NO: 1268519-99-8
• Molecular Formula: C15H19NO4
• Molecular Weight: 277.31566
• Mol File: 1268519-99-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3S,4R)-1-benzyl-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4R)-1-benzyl-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid(1268519-99-8)
• EPA Substance Registry System: (3S,4R)-1-benzyl-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid(1268519-99-8)

Safety Data

• Hazardous Substances Data: 1268519-99-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3S,4R)-1-benzyl-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid is used as a pharmaceutical candidate for its potential diverse biological activities. The presence of a carboxylic acid group and the specific stereochemistry suggest that it could be effective against various diseases, including viral, bacterial, and fungal infections.
Used in Organic Synthesis:
(3S,4R)-1-benzyl-4-(ethoxycarbonyl)pyrrolidine-3-carboxylic acid is used as a building block in organic synthesis for the preparation of other novel compounds. Its unique structure and functional groups make it a valuable component in the development of new chemical entities with potential applications in various fields.

Upstream product

• 2459-05-4 (E)-4-ethoxy-4-oxobut-2-enoic acid 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 

Relevant articles and documents

3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION

The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The substituted pyrrolidine compounds are of the formula (I), wherein R1, R2, R3, R4, R5 and T are defined as in the specification.

ORGANIC COMPOUNDS

Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel inter-mediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula (I), wherein the substituents are as described in the specificacion.